Nilotinib, 98%, an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity

Name: Nilotinib, 98%, an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity | 641571-10-0
Brand: J&K Chemical
SKU: JK906995_100_MG
Price: 226.7 USD
Availability: OutOfStock

Cat. No JK906995_100_MG

Vendor: J&K Chemical

Product Information

Product Name

Nilotinib, 98%, an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity

Brand Name

J&K

Product Number

906995

CAS

641571-10-0

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

644241

IUPAC Name

4-methyl-N-3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminobenzamide

InChI Key

HHZIURLSWUIHRB-UHFFFAOYSA-N

SMILES

CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity

Publication Name: Cancer immunology, immunotherapy : CII

Publication Date: 2026-03-02

DOI: 10.1007/s00262-026-04335-w

Basophilic Blast Crisis: Rare Occurrence in Chronic Myeloid Leukemia

Publication Name: Indian Journal of Hematology and Blood Transfusion

Publication Date: 2026-02-26

DOI: 10.1007/s12288-026-02355-1

The Role of Protein Aggregation in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

Publication Name: Current Behavioral Neuroscience Reports

Publication Date: 2026-02-23

DOI: 10.1007/s40473-026-00320-w

ASO Author Reflections: The Potential of Bidirectional Chemotherapy for Peritoneal Carcinomatosis

Publication Name: Annals of Surgical Oncology

Publication Date: 2026-02-22

DOI: 10.1245/s10434-026-19302-z

Cytoreduction is a Valid Option for Treatment and Prevention of Anaphylaxis in Systemic Mastocytosis: Case Report and Literature Review

Publication Name: Clinical Reviews in Allergy & Immunology

Publication Date: 2026-02-21

DOI: 10.1007/s12016-026-09137-7

Nilotinib, 98%, an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity

Product Information

General Information

Safety Information

References Data Source From Pubchem

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity

Basophilic Blast Crisis: Rare Occurrence in Chronic Myeloid Leukemia

The Role of Protein Aggregation in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

ASO Author Reflections: The Potential of Bidirectional Chemotherapy for Peritoneal Carcinomatosis

Cytoreduction is a Valid Option for Treatment and Prevention of Anaphylaxis in Systemic Mastocytosis: Case Report and Literature Review